SCHEMBL2104493

SCHEMBL2104493

Clc1ccc(-c2cccc(Cc3c[nH]cn3)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.41
HRH3 Q9Y5N1 2/20 0.40
AOC3 Q16853 2/20 0.39
TKT P29401 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
SHMT1 P34896 1/20 0.37
SHMT2 P34897 1/20 0.37
CYP2C9 P11712 1/20 0.36
NR4A2 P43354 1/20 0.36
KCNH2 Q12809 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
CYP17A1 P05093 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP1A2 P05177 1/20 0.35
ADAMTS5 Q9UNA0 1/20 0.35
MAOB P27338 1/20 0.35
HSP90AB1 P08238 1/20 0.35
CHKA P35790 1/20 0.35
PSD A5PKW4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2102562 0.88 HRH3 (0.51) PTPN5HRH3
SCHEMBL2105133 0.83 PNMT (0.43) TAAR1GABRA1GABRB2CYP3A4
SCHEMBL11047959 0.80 HSP90AB1 (0.47) TAAR1GABRA1GABRB2HSP90AB1
SCHEMBL9033928 0.80 SMN1; SMN2 (0.38) TKTNR4A2GABRA1GABRB2MAOB
SCHEMBL2100722 0.80 LMNA (0.45)
SCHEMBL11045854 0.74 DAO (0.42) HRH3TAAR1CYP2C9
SCHEMBL28260269 0.74 DAO (0.42) TAAR1
SCHEMBL7666269 0.74 CYP19A1 (0.46)
SCHEMBL9027127 0.74 MAPT (0.41) CYP2C9CYP3A4CYP1A2
SCHEMBL9027973 0.74 IDO1 (0.52) CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158668-B2 Methods for treating CNS disorders with 4-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-17 US disclosed
EP-1981880-B1 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS HOFFMANN LA ROCHE (CH) 2010-02-24 EP disclosed
EP-1981880-A2 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS F.HOFFMANN-LA ROCHE AG (CH) 2008-10-22 EP disclosed
US-20070197622-A1 Methods for treating CNS disorders with 4-imidazole derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 US disclosed
WO-2007085556-A2 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197622-A1 Methods for treating CNS disorders with 4-imidazole derivatives CRY1, GPR119, MTNR1A PTPN5 2817/4885HRH3 213/4885AOC3 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.